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ABSTRACT 
Influenza is a common infectious disease resulting from a frequently mutated RNA virus. 
Vaccination is currently the most effective method to prevent people from seasonal or pandemic 
influenza. The production of traditional egg-based influenza vaccine is time-consuming and 
provides limited effect against new strains. Therefore, it is necessary to develop a rapid method 
to produce influenza vaccines. We proposed a novel influenza vaccine based on the E.coli 
expression system. Hemagglutinin (HA) is the major target surface protein of influenza virus for 
vaccine development. In this study, we sub-cloned the HAs encoding gene into an E. coli 
expression vector; the signal peptide sequence, the transmembrane and cytoplasmic domains of 
the whole HA of H5N1 (A/Vietnam/1203/2004) were removed. Expression of recombinant HAs 
fused with a C-terminal His-tag was investigated and confirmed through SDS-PAGE and 
Western blot assay. After being purified under denaturing conditions using NTA-Ni affinity 
chromatography, HAs were dialyzed for refolding. We obtained concentrated recombinant HAs 
from bacterial cultures at a yield of 250 µg/ 500 ml.  Finally, animal studies revealed the 
production of anti-HA antibodies in mice immunized with different doses of the recombinant 
HAs. We also compared the adjuvant effects of iron oxide nanoparticle (IONs) and selected 
commercial adjuvants. These results suggest that this system has the potential to be a new 
method for the mass production of influenza vaccines at low cost. More efforts are going to be 
focused on the adjuvant effect of IONs in future work. 
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I.  INTRODUCTION 
1.1 Influenza 
1.1.1 Influenza virus 
Influenza, usually known as ‘the flu’, is an infectious disease resulting from a RNA virus of the 
family of Orthomyxoviridae. The influenza viruses can cause influenza in many species of 
vertebrates including birds, humans and other mammals. In humans, it is typically transmitted 
through the air by coughs or sneezes, by direct contact with bird droppings or nasal secretions, or 
by contact with contaminated surfaces. The classic symptoms of influenza include fever, myalgia, 
sore throat, nonproductive coughing and headache. Additional symptoms may appear such as 
runny nose, eye pain and substernal chest burning (1). 
There are three immunologic types of the influenza virus: Type A, Type B and Type C. Although 
wild aquatic birds are the natural carriers of various Type A influenza viruses (2), this kind of 
influenza virus occasionally transmits to other species and causes pandemics. Both Type B and 
Type C viruses are less common then Type A influenza viruses. Type B only infects humans, 
seals and ferrets, while Type C only infects humans, dogs and pigs. Among these three genera of 
influenza viruses, Type A virus is considered as the most virulent human pathogens (3).   
Based on the antibody response to these viruses, the influenza viruses could be further 
subdivided into different serotypes. Influenza A viruses are classified by their two surface 
antigens: Hemagglutinin (HA) and Neuraminidase (NA) (4). Up to now, 16 HA subtypes (H1-
H16) and 9 NA subtypes (N1-N9) have been identified. The virion, the entire virus particle, is 
commonly roughly spherical and about 80-120nm in diameter. Their ultrastructural details can 
be depicted by the negative-stained transmission electron microscopy (TEM), as shown in Fig. 
1.1(A). The nomenclature of the influenza viruses is expressed in this order: 1) virus type, 2) the 
2 
 
first geographic site where it was isolated, 3) strain number, 4) year of isolation, and 5) subtype 
of virus (Fig. 1.1[B]). For example, the antigen produced in this study is from genomes of 
A/Vietnam/1203/2004(H5N1), and it is an H5N1 influenza A virus which was first isolated from 
Vietnam in 2004. 
The molecular structures of the three different types of influenza viruses are similar. As shown in 
Fig. 1.1(C), the Influenza A viral envelope is wrapped with spikes of two main glycoproteins: 
HA and NA. In the central core are the viral RNA genome and other viral proteins. The RNA 
genome consists of eight pieces of segmented negative-sense RNA, each containing one or two 
Fig. 1.1 A. Electron microscopy images of influenza viruses (67). B. 
Nomenclature of influenza viruses (1).  C. The molecular structure of influenza 
A virus. Figure is adapted by permission from Macmillan Publishers Ltd: [Nature 
Reviews Genetics] (65), copyright (2007).  
 
A.  C. 
B. 
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genes. These RNA segments encode eleven proteins: HA, NA, nucleoprotein (NP), matrix 
protein M1 and M2, nonstructural protein NS1 and NS2, and polymerase subunit PA, PB1 and 
PB2. Previous research revealed that four of these proteins: HA, NA, NP and M1 are the 
important targets of host immune response. Because NP and M1 proteins are located inside the 
virus, the humoral and cellular responses they elicit cannot neutralize the virus. Therefore, HA 
and NA are the prime candidate antigens for developing influenza vaccine (5).  
1.1.2 Characteristics of Hemagglutinin 
HA is a trimeric protein composed of three monomers; HA1, HA2, and HA3 domains. The 
trimeric protein is divided along the longitudinal axis of the protein to a globular domain and a 
stem domain. As shown in Fig. 1.2, the beta-sheets are primarily present in the globular domain 
where the binding region to sialic acid locates, while the stem region of the HA is made of the 
alpha helices. 
The full length HA gene sequence consists of signal peptide, two subunits: HA1 and HA2, 
transmembrane polypeptide and cytoplasmic domain. In this study, we removed the amino-
terminal 16 bp signal peptide, the transmembrane polypeptide and cytoplasmic domain at its C 
terminus to avoid targeting after protein translation. Thus, the calculated molecular weight of the 
truncated HAs monomer in influenza A virus A/Vietnam/1203/04 (H5N1) is 58.7 kDa with an 
isoelectric point of 6.59 based on the protein sequence using online calculator (6). 
As the most abundant surface glycoproteins of influenza virus, HA has been recognized as a key 
antigen in the host response to the influenza virus in both natural infection and vaccination. The 
main function of HA is to mediate the binding of virus to target cells and the entry of the viral 
genome into the target cells (2). Upon HA’s binding to the sialic acid sugars on the surfaces of 
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epithelial cells in the nose, throat, lungs of mammals and intestines of birds, the virus enters the 
target cell by endocytosis. HA is one of the main determinants of the host range of influenza A 
viruses due to its specificity for receptor recognition and binding. Moreover, conserved 
insertions of peptides adjacent to the cleavage site between HA1 and HA2 were found in several 
highly pathogenic avian A viruses H5N1. HA is also important to determine the virulence of 
avian influenza A viruses in poultry (7). Among different subtypes, H5 and H7 have a highly 
cleavable HA so that they may infect humans and result in pandemics (5). 
Fig. 1.2. The three-dimensional structure of the influenza HA monomer and 
trimer. Figure was made by André van Eerde (University of Groningen), using 
MOLSCRIPT, according to file from Protein Data Bank, code 3HMG (68).  
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1.1.3 Influenza pandemic 
In the 20th century, four influenza pandemics occurred and each resulted from new strain of the 
virus in humans. The 1918 ‘Spanish influenza’ H1N1 virus which originated from an avian virus 
adapted to transmit efficiently in humans. It resulted in such a severe pandemic that the total 
deaths were estimated at approximately 50 million in a worldwide range (8). Besides, all the 
other pandemics were related to this H1N1 virus. The mechanisms of the origination of the first 
three pandemics are presented in Fig. 1.3. The reassortment of 1918 H1N1 and other avian 
viruses led to the 1957 ‘Asian influenza’ H2N2 virus and 1958 ‘Hong Kong influenza’ H3N2 
virus, separately. The latest pandemic influenza happened in 2009 (subtype A/H1N1).  
In order to circumvent the immune responses of the host animals, the viral genomes mutate 
frequently. Usually, the sites on HA and NA proteins that are recognized by the host immune 
system are under constant selective pressure. The variation of influenza viruses, which are due to 
antigenic drift (mutations on HA and NA) and/or antigenic shift (re-assortment of the subtypes of 
viral gene segments), could cause an influenza epidemic or pandemic if the population has no 
inherent immunity against the new strain. New influenza strains appear 1) when existing viruses 
in other species adapt to human hosts; 2) existing human viruses genetically re-assort genes from 
viruses which usually infects birds or pigs. For example, the 2009 H1N1 is a novel influenza 
virus that combines genes from human, swine and bird flu viruses. A pandemic of influenza may 
begin with isolated cases, exploding when the virus evolves the ability to transmit efficiently in 
humans. 
H5N1, the focus of this study, is a highly pathogenic avian influenza virus which resulted in 
severe disease with high morbidity and mortality, devastating poultry industries worldwide. 
Generally, people are not susceptible to be infected by H5N1, but mutated viruses started to 
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infect humans and cause severe diseases and death. As early as 1997, an avian H5N1virus 
(A/Hong Kong/156/97) was isolated from a three-year-old boy with a fatal illness consistent with 
influenza in Hong Kong. Molecular analysis of the gene segments showed that the H5 in this 
strain was from a turkey influenza virus in 1991 (7). Six of eighteen individuals died since the 
first report of the human H5N1 infection. The virus temporarily disappeared in human 
population but remained in birds in South East Asia until it recurred in humans in 2003 and 2004. 
Cases that infect humans were thought to be brought from close contact with poultry, while the 
first account of probable human-to-human transmission was published Jan 2005 documenting a 
mother in Thailand who probably contracted virus from her daughter in Sep 2004 (9) . From 
2003 to the writing of this thesis (Oct 2013), H5N1 has resulted in 641 WHO-confirmed 
infections and 380 deaths with a mortality rate of 59.3% (10). 
Concerns were raised whether large amounts of funds should be provided to research developing 
vaccines against H5N1 since it has limited transmission among humans (11). For short-term 
interests, it is true that research funds need to be invested on researches on other more 
devastating diseases. However, in a long-term view, this highly pathogenic virus is one of the 
candidate viruses for pandemic preparedness (12). WHO data mentioned above already showed 
the high morbidity and mortality rates brought from the H5N1 infection in humans. Though most 
of them bring seasonal infections with light symptoms in humans, it is never wise to 
underestimate the potential impact of new strains. During its geographic spread, the H5N1 virus 
underwent antigenic drift and/or shift as all other influenza viruses (13). Since the H5N1, H1N1 
and other subtype of influenza virus coexist in the same environment, we must give more 
attention to the risk of potential pandemic spread. Considering that the viruses mutate rapidly, 
researchers should maintain their interest in improving pandemic influenza vaccines despite the 
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fact that public concern has subsided. We have reason to believe that if the H5N1 virus picks up 
the capability to transmit among humans, it may cause a worse pandemic than 1918 Spanish flu.  
1.2 Development of Influenza vaccination  
1.2.1 Traditional egg-based vaccines 
Vaccine, antiviral drugs and personal preventive care are the common methods for influenza 
prevention. Among them, vaccination of public is the most effective way to combat influenza. 
Embryonated eggs have been employed in the production of influenza virus since 1937, because 
they can produce large amounts of virus to be processed to inactivated vaccines in a safe and 
relatively low cost method (14). The inactivated vaccines consist of whole inactivated virus, 
detergent-split virus or purified HA and NA subunits. Currently, the most common vaccine used 
against the seasonal influenza is the trivalent influenza vaccine (TIV) that contains inactivated 
antigens from two influenza A virus strains and one influenza B virus strain. The three influenza 
strains selected by WHO are propagated in chicken eggs, chemically inactivated and semi-
purified (15). An alternative approach is the live-attenuated influenza vaccines (LAIV) based on 
a cold-adapted and temperature sensitive virus (16). They are also cultured in eggs but 
administrated by nasal spray. 
The major limitations of these egg-based vaccines are the long production time and requirements 
for large amounts of eggs (Table 1.1). Because natural viruses are usually not able to grow well 
in eggs, re-assortment of genes between the new virus strain and an egg-adapted strain such as 
A/Puerto Rico/8/34(PR8) (H1N1) is required through traditional or reverse genetics technology. 
It may take up to ten months to screen a suitable candidate virus for vaccine due to the variety of 
production yield of different strains. Even though these egg-based vaccines are effective to the 
annual seasonal influenza with the predicted strain, the speed to produce them is far from rapid 
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enough to fight any sudden breakout of pandemic strain. On the other hand, this method does not 
work for viruses that are lethal to chicken embryos such as H5N1 strain (17). Also, individuals 
who are allergic to egg cannot accept vaccine produced by this method.  
The incapability of worldwide-scale production is another challenge for influenza vaccine 
development. The gap between the expected demands for future pandemic influenza vaccines 
and global production capacity need to be bridged (14). Obstacles such as high cost, troublesome 
distribution and administration logistics of current flu vaccines are the main reasons that prevent 
people in developing countries from receiving vaccination. Thus, it is essential to develop new 
technologies to realize rapid, massive and low cost production of influenza vaccines. 
1.2.2 Development of novel vaccines using new technologies  
Due to the limitations of egg-based vaccines, other approaches have been studied to replace them. 
One approach is to develop culture-based vaccines. The influenza viruses are cultured in cell-
filled bioreactors that do not rely on the maintenance of huge flocks of chickens; this may result 
in a shortened production period. Up to now, efforts have been made to produce influenza 
vaccine using Vero, Madin-Darby canine kidney (MDCK) or PERC.6 cell-cultures (14). Among 
them, MDCK cells are most suitable for production of influenza viruses in serum-free media. 
Drug safety studies showed that the MDCK cell line is safe for biological production (18) and 
Phase I clinical trials showed that split vaccines derived from cell culture is highly immunogenic 
in adults (19). Another group compared formalin-inactivated influenza B virus vaccines 
propagated in different host system and showed that the cell-culture based vaccines were as 
effective as egg-based vaccines (20). Currently, Sanofi Pasteur, Novartis and Solvay produce 
mammalian cell culture influenza vaccines licensed in Europe or in the US (16). However, cell 
culture systems have drawbacks such as the difficulty in scale-up production and occasional 
10 
 
contamination. Also, the application of mammalian cell lines may introduce specific mutations 
which result in structural changes of the antigen, which in turn diminishes the efficacy of the 
vaccines (21; 22).  
DNA vaccination is a promising vaccine technology. It is easy to manipulate: simply inject small 
genetically engineered DNA encoding the antigen instead of using the antigen itself. One of its 
advantages is the fast production and ease of storage. DNA vaccines against new influenza 
strains can be produced in weeks, rather than months, and the vaccine stock can last years 
without refrigeration. In addition, studies showed that DNA vaccines induce both major 
histocompatibility complex (MHC) class I and II responses (23) and long- term humoral and 
cellular immune responses (24). As for DNA influenza vaccines, one encoding HA protein was 
exhibited to be safe and immunogenic by intramuscular and intradermal routes in humans in 
phase I clinical studies (25). The possibility of foreign gene integration to the host genome is a 
major concern about this type of vaccine. Also more clinical studies are needed to investigate the 
efficacy of DNA vaccines in humans. 
Another approach of egg-free influenza vaccine production is the development of recombinant 
protein (antigen)-based vaccines. The development of recombinant DNA technology realized the 
expression of viral proteins as antigens in the vaccine formulations, which are safer than the 
vaccines that use live, attenuated or killed pathogens. Moreover, it is easy to achieve rapid and 
massive production of proteins followed by purification and distribution. Several kinds of 
expression systems have been applied to express HA molecule from the influenza virus such as 
adenoviral virus (26) and baculovirus system (15). A recombinant multimeric H5 hemagglutinin 
protein (rH5) was successfully produced using a baculovirus expression vector system in SF+ 
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Table 1.1. Comparation of different methods to produce influenza vaccine 
insect cells (27). A virus-like particle (VLP) vaccine manufactured in Sf9 insect cells was 
evaluated by their humoral immune response in humans in an FDA-approved phase I/II clinical 
study (28). E.coli expression system is a mature system applied in the production of recombinant 
proteins. This is also an attractive system in influenza vaccine production because it provides fast, 
low cost and massive production of antigens. The doubling time of E.coli cells is as short as 20 
min, and up to 50% of the recombinant proteins locate in inclusion bodies which are easy to 
collect for purification. For decades, the correct folding, glycosylation and secretion of HA has 
Egg-based  vaccine 
Advantages • Safe, effective and relatively low cost 
Limitations • Screening of desirable virus strains is needed in advance 
• Lengthy manufacturing process: up to ten months 
• Rely on the maintenance of huge flocks of chickens 
• Not available for viruses which are lethal to chicken embryo 
• Not available for individuals with egg allergy 
Cell culture-based vaccine 
Advantages • Cultured in bioreactor , easier to handle 
• safe and as effective as egg-based vaccines 
Limitations • High-yielding re-assorted virus is needed 
• Difficulty in scale-up production 
• Cell line specific mutations which results in antigenic and structural 
changes of the HA protein may be introduced  
• Cross-contamination may occur during manufacturing process 
Recombinant protein (antigen)-based vaccine 
Advantages • Recombinant DNA technology is applied to produce the viral proteins 
• The antigens are purified and utilized as the active ingredients in vaccine 
Limitations • Weak immunogenicity 
12 
 
always been considered necessary for HA production in vaccine development. However, studies 
showed that the bacteria system without posttranslational modification could be used to produce 
effective influenza vaccines. Hana Golding and her team developed a bacterial system to express 
and purify properly folded globular domain HA1 of H5N1 which is immunogenic in mice and 
ferrets. Moreover, they first identified a functional N-terminal oligomerization sequence in HA1 
(29). The important obstacle to the development of antigen-based vaccine is the weak 
immunogenicity of the recombinant antigen protein. Although recombinant DNA technology 
allows fast and massive production of a single antigen, the immunogenicity of the antigen is 
usually limited. Accordingly, large antigen doses or repeat administration are required to produce 
an adequate immune response. To solve this problem, some vaccine additives have been 
investigated to combine with these antigens to maximize immunogenicity and manufacturing 
capacity.  
Considering that the current influenza vaccine needs to be updated every year to adapt to the 
antigenicity of the virus strains that are predicted to circulate in the next flu season, they will not 
be able to provide effective protection during the emergence of a novel strain of pandemic 
influenza virus. Therefore, efforts have been focused to develop a broadly cross-protective 
vaccine, known as ‘universal’ vaccines. Approaches are targeted at the conserved proteins such 
as the external domain of the influenza M2 ion channel protein and HA fusion peptides and stalk 
domains, but most studies are at the level of animal models (30). 
1.2.3 Adjuvants in influenza vaccines 
During the development of an influenza vaccine, it is essential to evaluate its safety and 
immunogenicity in special groups such as infants, pregnant women, immuno-compromised 
individuals or people over 65 years old. For example, the standard TIV offers relatively poor 
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efficacy for people over 65, the fastest-growing group in our population who suffer greater 
morbidity and mortality than the young when infected by influenza. Aging is related to decline in 
immune system functions, which results in less robust innate and adaptive immunity. Instead of 
increasing the dosage or number of immunizations, the addition of other components might 
induce a protective and long-lasting immune response.  
Adjuvants are such vaccine additives that act to accelerate, prolong or enhance antigen-specific 
immune responses when combined with the antigens (31). Products with effective adjuvant may 
benefit newborns, the elderly or immuno-compromised people (32). The word “adjuvant” comes 
from the Latin word“Adjuvare”which means “to help” (33). The adjuvant itself should cause 
no or minimal toxicity or immune effects. There are two classes of adjuvants applied in modern 
vaccine development (Table 1.2.). Immunostimulants mimick structures of evolutionarily 
conserved molecules, such as components of bacterial cell walls, endocytosed nucleic acids such 
as dsRNA, ssDNA, and unmethylated CpG DNA etc (34). These substances are also named 
pathogen-associated molecular patterns (PAMPs). Once antigens are combined with these 
adjuvants, cells in innate immune response systems, including dendritic cells (DCs), 
lymphocytes and macrophages will be activated as if attacked by a natural infection. Another 
type of adjuvant is a vehicle that presents the antigens to the immune system via controlled 
antigen release and depot delivery systems. 
Alum, referred to as aluminum salt based adjuvants, is one of the adjuvants in approved human 
vaccines. The antigens are adsorbed onto highly charged aluminum particles to formulate the 
vaccines. Alum adjuvants have been developed to elicit protective antibody responses. Their 
advantages include safety, simple formulation for large production, together with their capacity 
to augment the humoral responses by providing Th2 cells help to follicular B cells (35). 
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Meanwhile, alum adjuvants are limited in that they are not able to elicit cell-mediated Th1 or 
CTL responses against intracellular pathogens (36). Its inability to be frozen is another 
disadvantage.  
Oil-in-water (o/w) emulsions are other adjuvants applied in human vaccines. They are advanced 
to increase the breadth of cross-reactive antibodies and possess significant dose-sparing activity. 
Addition of oil-water based emulsion adjuvants offer a 4-fold dose sparing effect on standard 
egg-based vaccine (16). MF59TM, consisting of an o/w emulsion is used in Europe as an adjuvant 
in influenza vaccines. It improves the immune response to a H5N1 vaccine by inducing 
qualitative and quantitative expansion of the antibody repertoires with protective potential (37). 
Although it does not induce increased CD4+ Th1 immune responses like alum, it has the 
potential to be applied in influenza vaccines due to its capacity to increase the hemagglutination 
inhibiting antibodies and CD8+T-cell responses (38). Novartis developed Aflunov, an egg-
derived, subunit vaccine which received the approval from the Committee for Medicinal 
Products for Human use (CHMP) in adults aged above 18 years in September 2010. This pre-
pandemic vaccine consists of 7.5 µg HA from the avian A/H5N1 virus and adjuvant MF59. 
Studies have revealed that it meets the requirements for pre-pandemic vaccine: safety, ability to 
induce broad cross-neutralizing antibody response and ability to induce strong and long-lasting 
immunological memory (13).  
It is paramount to the effectiveness of adjuvants to activate DCs which results in enhanced 
presentation of the antigenic peptides on MHC class I and II to the TCR. A leading adjuvant 
targeting DC is the family of innate Toll-like receptors, particularly the LPS receptor, Toll-like 
receptor 4 (TLR4). TRIA Bioscience Corp. and protein Sciences Corp. are working on GLA-SE, 
a two-part adjuvant system comprised of glucopyranosyl lipid adjuvant (GLA), a formulated 
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synthetic TLR4 agonist, and a stable emulsion (SE) of o/w. This adjuvant together with 
recombinant HA was demonstrated to protect mice and ferrets against a high titer challenge with 
H5N1 virus. They successfully augment neutralizing antibody titers via Th1-mediated antibody 
responses (39).  
Current researchers usually focus on studies of antigens at the same time testing the antigens 
Table 1.2. Immune responses triggered by immunostimulants and vehicles or delivery 
systems. Adapted from (36). 
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with several adjuvants. It seems that no single adjuvant can produce broad and long-lasting 
immune responses that are required for all new vaccines. Challenges remain regarding how to 
develop novel adjuvants as well as how to standardize the adjuvants formulated in different 
laboratories or companies. 
1.3 Nanoparticles and their application in biomedical engineering 
1.3.1 Nanoparticles  
Without an international definition, nano-particles (NPs) usually refer to the particles with size 
smaller than 100 nm. Engineered NPs have been used to provide diagnostic, therapeutic and 
prognostic information about the status of disease. They are ideal for antigen delivery for several 
reasons. 1) Based on their high surface ratio, function groups can be added on their surface to 
attach target reagents. 2) Their hydrodynamic size from 10-100nm could prevent their 
elimination from blood by kidney or liver. 3) Their near-neutral zeta-potential could minimize 
the nonspecific interaction with blood components. 4) They are highly stable in physiologically 
relevant media (40). Therefore, NPs are potential vaccine delivery platforms or adjuvants for 
vaccine development.  
Because their size is comparable to pathogens, NPs can be efficiently recognized by immune 
cells and facilitate the delivery of antigens to antigen presenting cells (APCs). Different 
strategies to design NPs targeting DCs are described in Fig. 1.4, as DCs, the major APCs, play 
important role in both innate and adaptive immune responses. The antigen can be attached to the 
surface of NPs via chemical or physical interaction; the antigen can also be encapsulated inside 
the nanoparticles so that it is protected from degradation. Additionally, NPs can combine with 
biological molecules as address labels to guide vaccines to specific sites in vivo (41; 42; 43). 
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1.3.2 Current application of NPs in vaccination 
NPs have been widely applied in vaccine development due to the advantage of their small size, 
high drug-loading capacity, controllable drug release, etc (44). NPs can be broadly classified into 
three categories: liposomes, polymers, and inorganic nanomaterials (45). Those applied in 
vaccine approaches include liposomes, nano-emulsions, polymeric NPs, dendrimers and 
immunostimulatory complexes (ISCOM) (46). Lipid polymers PLGA have been applied to 
delivery Hepatitis B virus (HBV) surface antigen (47) and fusion peptide and GM-CSF DNA 
(48). Self-assembling protein nanoparticle (SPAN) was used for peptide sporozoite malaria 
vaccine (49).  
Approaches to the application of NPs as biomedical vehicles face many challenges. NPs can be 
removed by phagocyte cells. The NPs carrying antigens can be degraded if they cannot move out 
of endosome. For those antigens which are encapsulated inside NPs, their antigenicity might be 
destroyed during the encapsulation process. To delay the macrophage-mediated clearance of NPs, 
a group of researchers fused ‘self-peptides’ CD47 to the NPs to pretend that these NPs are self-
molecules. Thus, persistent circulation of these NPs can be promoted (50).   
Up to now, few attempts have been made to apply solid inorganic nanoparticles as a vaccine 
delivery platform. Iron oxide nanoparticles (IONs) are one kind of solid inorganic nanoparticles. 
They are suitable for many biomedical applications due to their good biocompatibility, magnetic 
characteristics, the availability for multiple surface functionalization, and low cost (51; 52). They 
have been applied in optical imaging and magnetic targeting in tumors (53), targeting primary 
breast cancers and metastases (54), and delivery of antibodies against breast cancer (55).  
IONs have safety profiles, prior uses in drug delivery, and low cost of production. Surface 
modification makes it available to conjugate with proteins, peptides and DNA (56). Therefore, it 
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is a potential delivery platform for vaccines. Considering peptides are generally not very 
immunogenic on their own and require additional components to stimulate an adequate response 
(57), IONs may function as adjuvants to stabilize antigens and increase cellular uptake, 
trafficking and presentation of the antigens. George Hui, et.al first demonstrated that iron oxide 
nanoparticles could be applied as a clinically acceptable vaccine delivery platform without 
additional adjuvants (58).  
Fig. 1.4. Different strategies of nanoparticle (NPs) targeting. Figure is 
adapted from (41). 
19 
 
1.3.3 ION as delivery platform of influenza vaccine 
We hypothesized that the ION could display as a delivery platform for influenza vaccine and 
present the peptides to DCs and elicit subsequent adaptive immune response without additional 
adjuvants. In order to testify this hypothesis, we developed a HA subunit influenza vaccine 
delivered by ION in this study. The recombinant HAs (HA without the transmembrane 
polypeptide and cytoplasmic domain) from influenza A virus A/Vietnam/1203/04 (H5N1) was 
sub-cloned into an E.coli expression system. After confirming the correct expression of HAs in 
bacterial cultures, we purified and refolded the recombinant HA proteins. Furthermore, the 
immunogenicity of the noval nano-vaccine was characterized in Balb/c mice. The mice were 
immunized with different doses of HAs with the addition of IONs or commercial adjuvants to 
investigate the anti-HA antibody responses elicited in the immunized mice. Therefore, we 
explored the immunogenicity of the recombinant HAs and compared the adjuvant effects of 
IONs and the commercial adjuvants. 
 
 
  
20 
 
II. MATERIALS AND METHODS 
2.1. Plasmid constructs 
2.1.1. Expression system 
 
Fig. 2.1. A plasmid map of the pTAGBP vector. 
pTAGBP, an established expression vector from Dr.Ye’s lab (shown in Fig. 2.1.), was 
constructed from pTrcHis2-TOPO (Invitrogen Corporation,Carlsbad, CA). The DNA sequence 
of HA protein was amplified from pCDNA3.01/HA/optimized provided by Dr.Gao (26).  
The pTAGBP vector has important elements as listed below:  
 The trc promoter is a hybrid promoter containing the –35 region from the trpB 
promoter and the –10 region from the lacUV5 promoter. This hybrid promoter works 
sucessfully for high-level expression in E. coli. 
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 The lacO sequence is an important operator in this expression system. It is the 
binding site of the Lac repressor encoded by lacIq gene. In the absence of IPTG, Lac 
repressor binds to the lacO sequence and represses transcription. The binding between 
IPTG and Lac repressor results in the deattachment of Lac repressor from the LacO 
sequence so that the expression is induced. 
 rrnB antitermination sequence functions to reduce premature transcription termination. 
 T7 gene 10 translational enhancer sequence strenghtens the translational initiation.  
 The minicistron containing nucleotides that are efficiently translated in prokaryotic 
cells is included in this vector to enhance translational efficiency. 
 The C-terminal 6xHis tag serves for purification of the recombinant proteins. 
2.1.2. Plasmid extraction 
E.coli was grown in Luria-Bertani media (LB broth, 1.0% Tryptone, 0.5% yeast extract, 1.0% 
NaCl, pH 7.0, Thermo Fisher Scientific Inc., Rockford, IL) supplemented with 0.4% Glucose 
and 100 μg/ml Ampicillin when necessary. To extract the plasmids, a portion of 10 µl E.coli 
glycerol stock (kept at -80ºC) of pCDNA3.01/HA/optimized was added into 5 ml LB media and 
incubated at 37 ºC with a speed of 250 rpm overnight. The plamids were extracted using 
PureYield™ plasmid miniprep kit (Promega Corporation, Madison, WI): a portion of 3 ml 
overnight bacteria culture was collected by centrifuging in a microcentrifuge for 30 s at 13,000 
rpm, and the supernatant was discarded. The pellets were resuspended in 600 µl deionized water 
(dH2O). To prepare the lysate, 100 µl of Cell Lysis Buffer (Blue) was added into the mixture and 
the tubes were inverted 6 times. After that, 350 µl of cold (4–8°C) Neutralization Solution was 
added into the mixture and mixed thoroughly by gently inverting. The debris after lysis was 
removed by centrifuging at 13,000 rpm in a microcentrifuge for 3 min. Without disturbing the 
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cell debris pellet, the supernatant containing the DNA (~900 µl) was transferred to a 
PureYield™ Minicolumn and centrifuged at 13,000 rpm for 15 s. The flowthrough was removed, 
and the minicolumn, with the DNA bound to its matrix, was put back into the same collection 
tube. To wash the minicolumn, 200 µl of Endotoxin Removal Wash (ERB) was added to the 
minicolumn and centrifuged at 13,000 rpm for 15 s. A volume of 400 µl Column Wash Solution 
(CWC) was added to the minicolumn followed by centrifuging at 13,000 rpm for 30 s. Before 
eluting the plasmid DNA, the minicolumn was transferred to a clean 1.5 ml microcentrifuge tube, 
then 30 µl of nuclease-free water was added directly to the minicolumn matrix. After standing 
for 1 minute at room temperature (RT), the plasmid DNA was eluted by centrifuging for 15 s. A 
volume of 2 µl eluted plasmid DNA was dropped onto Take3 plate to measure its concentration. 
The rest was stored at –20°C for further use.  
2.1.3. Polymerase Chain Reaction (PCR)  
The cytoplasmic and transmembrane domain sequences of the HA were removed from the HA 
gene during PCR amplification and the truncated HA gene was referred as HAs. The 
pCDNA3.01/HA/optimized plasmid extracted from E.coli was used as a template for PCR. The 
Spe I and Sal I restricted sites in the pTAGBP vector were selected for subcloning of HAs. For 
construction of the HA expression vector, the following set of PCR primers was used: HAs 
(forward) (5’-ATAGACTAGTGATCAGATCTGCATCGGT-3’) and HAs (reverse) (5’- 
ACGCGTCGACATAGATGCCGATACTC-3’). The truncated HA gene was amplified by PCR 
with PhusionTM polymerase (New England Biolabs Inc., Ipswich, MA) in the presence of 
PhusionTM HF buffer (1.5 mM MgCl2). The reaction system (50 µl) comprised of the following 
components: 5×PhusionTM HF buffer (10 µl), 10 mM dNTPs (1 µl), forward primer (1 µl), 
reverse primer (1 µl), template plasmid (1 µl, ~6ng), PhusionTM DNA polymerase (0.5 µl) and 
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deionized H2O (dH2O, 35.5 µl). Applied Biosystem 2720 Thermal Cycler was used to run the 
reaction. The PCR was carried out under the following conditions: initial denaturation at 98C 
for 30 s, denaturation at 98C for 10 s, annealing at 51C for 30 s and extension at 72 C for 48 s, 
repeated for 25 cycles and final extension of 72C for 10 min.  
After the PCR finished, a portion of 5 μl PCR product was mixed thoroughly with 1μl 6×DNA 
loading buffer (2.5% Ficolli-400, 11 mM EDTA, 3.3 mM Tris-HCl [pH 8.0], 0.017% SDS and 
0.015% bromophenol blue, New England Biolabs Inc.) and analyzed by DNA electrophoresis in 
0.8% agarose gel which contains 0.5 μg/ml ethidium bromide (EB). Quick-Load 1kb DNA 
ladder (New England Biolabs Inc.) was used as the marker. The gel was running in TAE (Tris-
acetate-EDTA) buffer at 100 V for 40 min. The size of the PCR product was checked by a 
ultraviolet transilluminator. The positive products were purified using MinElute PCR 
Purification Kit (Qiagen Inc., Valencia, CA) by following a protocol provided by manufacturer. 
2.1.4. Enzyme digestion 
A portion of 1 µg of the HAs amplified sequence and the pTAGBP vector was double-digested 
in separate reactions using SalI-HF and SpeI (New England BioLabs Inc.). The other 
components of the digestion system include 10×buffer 4 (2 µl), SalI-HF (20,000U, 0.5 µl), SpeI 
(10,000U, 0.5 µl), 100× bovine serum albumin (BSA, 0.2 µl) and dH2O to make the total volume 
of the reaction system 20 µl. The mixture was incubated at 37℃ for 1 h. 
To check whether the HAs sequence and vector were correctly digested by the restriction 
enzymes, the products were mixed thoroughly with 4 μl 6×DNA Loading buffer and loaded onto 
0.8% agarose gel which contains EB. The gel was running in TAE buffer at 100V for 40 min. 
After checking their sizes, the DNA bands were excised from the agarose gel and then purified 
24 
 
using gel extraction kit (Qiagen Inc.): three columes of Buffer QG was added to 1 volume of gel 
(100 mg~100 ul). The gel was dissolved by incubating at 50℃ for 10 min. Then one gel volume 
of isopropanol was added to the sample to increases the yield of DNA fragments <500 bp and >4 
kb. To load DNA, the sample was applied to the QIAquick colume and centrifuged for 1 min at 
13,000 rpm. The flowthrough was discarded and 0.75 ml of Buffer PE was added to wash the 
column and centrifuged for 1 min. After centruging for an additional 1 min, the QIAquick 
column was put into a clean 1.5 ml microcentrifuge tube. A volume of 50 ul dH2O was added to 
the center of the QIAquick membrane to elute the DNA. After standing for 1 min, the column 
was centrifuged for 1 min. The purified DNA was stored at -20 ℃. 
2.1.5. Ligation 
T4 DNA Ligase Kit (Thermo Fisher Scientific Inc.) was applied to join the restriction enzyme 
generated DNA fragments. This enzyme catalyzes the formation of a phosphodiester bond 
between juxtaposed 5’-phosphate and 3’-hydroxyl termini in duplex DNA. The insert DNA was 
5:1 molar ratio over vector. The components of the reaction included 10×T4 DNA Ligase Buffer 
(2 µl), vector (2 µl), HAs insertion (1.5 µl) and dH2O (13.5 µl). The reaction occurred by 
incubating at 22℃ for 10 min. Thus, the HAs inserts were sub-cloned into pTA vector and the 
resultant expression plasmids were referred to as pTAHAs, as shown in Fig.2.2.  
2.2. E.coli Transformation  
2.2.1. E.coli strain 
After the recombinant E.coli strain pTAHAs was completed, the vector was transferred into NEB 
5- α competent E. coli [fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 ] (New England Biolabs Inc.). This DH5αTM have several features to 
make it suitable for recombinant DNA sub-cloning:  
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 Δ(lacZ)M15 allows for blue/white screening for recombinant cells through α-
complementation of the β-galactosidase gene. 
 The recA1 mutation reduces homologous recombination and prevents the cloned 
plasmids from being alternated. 
 The endA1 mutation incapacitates the activity of nonspecific endonuclease I to enhance 
the high quality plamid preparations. 
 The hsdR17 mutation deactivates the restriction endonulease of EcoKI enzyme complex 
so that the unmethylated DNA from foreign plasmid can be efficiently transformed. 
 
 
 
Fig. 2.2. Plasmid maps of pTAHAs expression vector. 
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2.2.2. Heat shock method 
The competent cells are bacteria which can accept extra-chromosomal DNA or plasmid. The 
commercial competent cells can uptake the ligated recombinant plasmids by heat shock method. 
The competent cells were thawed on ice for 10 min in advance. When the ligation finished, 7 μl 
ligation product was added into 25 μl DH5α competent cells and the mixture were put on ice for 
30 min, followed by heating at 42 C for 30 s. After incubating for another 5 min on ice, the 
mixture was added into 475 μl SOC media (0.5% Yeast extract, 2% Tryptone , 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4 , 4% glucose) provided along with the competent cells 
by New England Biolabs Inc. and shaked at 37C for 1 h with a vigorous shaking at 150 rpm in 
an incubator shaker. A volume of  50 μl or 100 μl of cells were spread onto LB selection plates 
(1.0% Tryptone, 0.5% yeast extract, 1.0% NaCl, 1.5 % agar) containing 100 μg/ml Ampicillin 
and incubated overnight at 37℃. 
2.2.3. Verification of transformed plasmids 
To confirm the correct insertion,  five colonies were picked up from each plate and inoculated in 
5 ml LB media containing 100 μg/ml Ampicillin overnight at 37C with shaking at 250 rpm 
overnight. The plasmids of the recombinant E.coli were extracted using the same methods 
described in 2.1.3. After that, the plasmid were digested by the same restriction enzymes as 
described in 2.1.5. The size of the digested fragments were checked by DNA electrophesis (0.8 % 
agarose gel containing EB). 
Because mutations might happen during the cloning process, we need to further confirm the 
correction of the insertion via DNA sequencing. Samples which included 3.4 pmol primers, 300-
500 ng plasmid and dH2O with the total volume of 13 μl, were submitted to the UA DNA 
Resource Center for capillary sequencing. After confirming that the sequence of the colonies 
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were correct, 400 μl culure of each confirmed E.coli strains were mixed thoroughly with 100 μl 
100% glycerol and stored at -80℃. 
2.3. Expression of HAs proteins in E.coli 
2.3.1. Induction of the recombinant proteins 
To induce the expression of recombinant proteins in E.coli, a volume of 10 μl cell culture from 
storage tube was inoculated in 5 ml LB media (supplemented with 0.4% glucose and 100 μg/ml 
Ampicillin) and grown overnight at 37°C with shaking at 250 rpm overnight. The next day, a 
portion of 0.5 ml overnight culture was inoculated in 50 ml LB media with vigorous shaking. A 
volume of 1 ml sample was taken 16 h post cultivation to determine the cell density by 
measuring OD600 using a spectrophotometer. When the OD600 reached 0.6 which indicated that 
the cells were in mid-log phase, volume of cells equivalent to 1 OD600 was removed and 
centrifuged at 5,000 rpm for 10 min. The supernatant was aspirated and the cell pellet was frozen 
at -20°C as sample of 0 h. 
The inducer IPTG was added to the culture to a final concentration of 1mM. The culture was 
kept incubation at 37°C with shaking at 250 rpm. To determine the optimal induction time point, 
volume of cells equivalent to 1 OD600 was removed every hour for 8 h and treated as described 
above.  
2.3.2. Separation of soluble and insoluble expressed proteins 
The recombinant proteins expressed in bacteria usually form inclusion bodies when they are 
expressed at high levels. These inclusion bodies can be separated from bacterial cytoplasmic 
proteins easily by centrifugation. B-PER II bacterial protein extraction reagent (Pierce 
Biotechnology, Rockford, IL) was applied to effectively extract soluble proteins.  
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Frozen pellet bacterial cells were washed once with 1× PBS buffer (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, and 1.8 mM KH2PO4, pH 7.4) by centrifugation at 13,000 rpm for 5 min at 
4ºC. For Mini-Scale Bacterial Protein Extraction (1.5 ml bacterial culture, OD600 = 1.5-3.0), 
washed cells were re-suspended in 150 μl B-PER II reagent by vigorously vortexing until the 
cell suspension was homogeneous. After vortexing for additional 1 min, soluble proteins were 
separated from insoluble proteins by centrifugation at 13,000 rpm for 5 min at 4ºC. For Midi-
Scale Bacterial Protein Extraction (40 ml bacterial culture, OD600 = 1.5-3.0), washed cells were 
re-suspended in 2.5 ml B-PER II reagent by vigorously vortexing until the cell suspension was 
homogeneous. After the mixture was shaken gently at RT for 30 min, soluble proteins were 
separated from the insoluble proteins by centrifugation at 13,000 rpm for 15 min at 4ºC. 
The supernatant (soluble fraction) was collected and the pellet (insoluble fraction) was re-
suspended in same volume of B-PER II that used to extract the proteins. A volume of 20 μl 
fraction was mixed with 4 μl 6×loading buffer (375 mM Tris-HCl pH 6.8, 12% SDS, 30% 
glycerol, 600 mM DTT, and 0.12% bromophenol blue) for SDS-PAGE (Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) or Western blotting assay to determine the solubility of the 
recombinant protein. 
2.3.3. SDS-PAGE and western blotting 
The soluble and insoluble fractions from samples equivalent to 1 OD600, which were collected at 
different time points, were heated at 95 C for 5 min. The sample was mixed before and after 
the heating step by vortexing. After the samples cooled to RT, debris were removed by 
centrifuging at 15,000 rpm for 10 min. Polyacrylamide Tris-glycine gels (10%) were prepared 
using the components in Table 2.1. A portion of 15 μl supernatant was loaded per well onto the 
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gel with special gel loading tips, and 7 μl of Precision Plus Protein WesternC Standards (Bio-
Rad Laboratories, Inc., Hercules, CA) was loaded in separated well alongside the samples.  
10% Separating Gel  1 gel 2 gel 5% Stacking Gel  1 gel 2 gel 
dH2O 1.9 ml 4.0 ml dH2O 1.4 ml 2.7 ml 
1.5 M Tris (pH 8.8) 1.3 ml 2.5 ml 1.0 M Tris (pH 6.8) 250 μl 500 μl 
30% Acrylamide 1.7 ml 3.3 ml 30% Acrylamide 330 μl 670 μl 
10% SDS 50 μl 100 μl 10% SDS 20 μl 40 μl 
10% APS 50 μl 100 μl 10% APS 20 μl 40 μl 
TEMED 2 μl 4 μl TEMED 2 μl 4 μl 
Table 2.1.Components of SDS-PAGE gel (0.75 mm) 
Electrophoresis was performed in the TGS running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS, pH 8.3) at 100 V for 30 min (stacking gel) and then at 200 V for 1 h (separation gel). 
After electrophoresis, the gel was carefully removed from the cassette.  
For protein staining, the gel was immerged into staining buffer (0.25% Coomassie Brilliant 
Blue R-250 Staining solutions (Bio-Rad), 40% methanol, 10% acetic acid) for 1 h at RT with 
gentle mixing on a rotary shaker. To visualize the protein, the gel was then destained by 
destaining buffer (30% methanol, 10% acetic acid) at RT until the gel became transparent.  
For Western blotting, the proteins on the gel were transferred to nitrocellulose membrane. 
Fresh transfer buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS, 20% methanol, pH 8.3) was 
prepared and cooled at -20°C. A sheet of nitrocellulose membrane with the pore size of 0.45 µm 
(Bio-Rad Laboratories, Inc.) was cut to appropriate size. The membrane, the gel, filter papers 
(Bio-Rad Laboratories, Inc.) and sponges were pre-wet in transfer buffer and kept in 4°C for 10 
min. A “sandwich” blot assembly was packed as: sponge-filter paper-gel-nitrocellulose 
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membrane-filter paper-sponge. All the bubbles in between were carefully removed by pipette 
during packing. The “sandwich” assembly was located in an ice tray which was placed in a box 
filled with cooled transfer buffer. Thus, the proteins on SDS-PAGE gel were transferred to 0.45 
µm nitrocellulose membrane in a constant voltage of 150 V for 50 min. After transferring, the 
membrane was carefully removed from the cassette using tweezers and incubated in a blocking 
buffer (1×PBS, 0.05% Tween-20, 5% non-fat dry milk) for 2 h with shaking at RT. After 
blocking, the membrane was incubated in mouse anti-HA antibody (BEI resource, Manassas, 
VA) diluted in non-fat dry milk/PBST (1×PBS, 0.05% Tween-20, 1% non-fat dry milk) at a 
ratio of 1: 500 (v/v) at 4ºC with shaking overnight. The membrane was then washed with PBST 
(1×PBS, 0.05% Tween-20) three times, 5 min each time, and incubated with anti-mouse IgG 
horse peroxidase (HRP) conjugated antibody (Sigma-Aldrich, St. Louis, MO) diluted at a ratio 
of 1: 2,000 (v/v) in non-fat dry milk/PBST. After shaking at RT for 1 h, the membrane was 
washed three times with PBST, 5 min each, followed by PBS, one time. Subsequently, the 
enhancer and stable peroxidase solutions (Thermo Fisher Scientific Inc.) were 1:1 (v/v) mixed 
and carefully loaded onto the membrane and incubated in dark for 5 min. The membrane was 
imaged using Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories, Inc.) and 
analyzed using PDQuest Analysis software (Bio-Rad Laboratories, Inc.).   
2.4. Purification of HAs proteins  
2.4.1. Solubilization of the denatured proteins 
A large volume of 400-500 ml culture was incubated and induced as described in 2.3.1. A 
portion of 0.75 ml buffer B (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea, pH 8.0) was added 
to the pellets collected from every 50 ml culture (3.5 h post induction). In order to solubilize the 
proteins inside the inclusion bodies, the pellets were re-suspended and shaken at RT for 2 h. The 
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Fig. 2.3. Usage of the Amicon Ultra 
concentration tube. Figure is adapted 
from product manual. 
supernatant was collected by centrifugation at 14,000 rpm for 20 min at 4 °C. Syringe filters 
with the pore size of 0.45 µm (EMD Millipore, Billerica, MA) were applied to filter the 
solubilized protein sample and all the buffers before use in the purification. 
2.4.2. Purification of HAs using NTA-Ni resin under denaturing conditions 
The Ni-NTA superflow slurry (Qiagen Inc.) was resuspended and poured into the column until 
1ml resin was settled. After that, the column was equilibrated with 5ml volumes of buffer B. 
Wash buffer C and elute buffer D were prepared with the same components but with pH 6.3 and 
pH 5.0, separately. A280 was measured by spectrophotometer to indicate the existence of proteins 
in solution. The sample was applied to column at a speed of 0.2 ml/min and washed with buffer 
B at a speed of 1 ml/min until the A280 is below 0.01. The column was then washed with buffer C 
until the A280 is below 0.01. Protein was finally eluted with buffer D with the speed of 0.2 
ml/min, collected by 1 ml/tube.  A volume of 20 μl of flow-through, wash fraction and each elute 
fraction were collected for SDS-PAGE assay.  
2.4.3. Dialysis and concentration of proteins 
The eluted proteins were refolded by removing the urea through dialysis. Float-A-Lyzer G2-20K 
( Spectrum Laboratories, Inc., Rancho Dominguez, CA) dialysis tubes were soaked in 10% 
ethanol followed by thoroughly flushing and soaking 
in dH2O before use. The sample was then loaded to 
the tube and refolded by stepwise dialysis against 
buffer 1 (6 M urea, 0.5 M NaCl, 1 mM DTT) at 4°C 
for 6 h. Buffer 1 was diluted against buffer 2 (25 mM 
Tris-HCl, pH 7.5, and 150 mM NaCl, 1 mM DTT, 
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0.1 mM EDTA). Sample was then dialyzed against 4M urea buffer for 6 h and against 2 M urea 
buffer for 8 h. Finally, proteins were dialyzed against buffer 3 (25 mM Tris-HCl, pH 7.5, 0.9% 
NaCl) for another 4 h.  
Amicon Ultra-0.5 (EMD Millipore) was applied to concentrate the dialyzed HAs proteins. The 
centrifugal filters with a pore size of 10kDa allow protein no larger than 30 kDa go through the 
membrane, so that the HAs protein (58.7 kDa) will remain in the inner collection tubes. As 
shown in Fig. 2.3., up to 0.5 ml sample was added to the Amicon Ultra filter device, followed by 
spinning at 14,000 g for 15 min. The concentrated solute was then recovered by placing the filter 
device upside down in a clean micro centrifuge tube and spun at 1,000 g for another 2 min. 
2.4.4. BCA Assay 
For quantification of the recovered proteins after dialysis, the concentration of proteins was 
detected by BCA Protein Assay kit (Pierce Biotechnology) using microplate procedure. Stock of 
BSA was 2-folded diluted from 2,000 μg/ml to125 μg/ml. A portion of 25 μl diluted BSA 
standard and dialyzed protein sample was added into wells of 96 well plate. The working reagent 
(WR) was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA Reagent B (50:1, 
Reagent A: B). A portion of 200 μl WR were added to each well. After mixing the samples and 
WR, the plate was covered and incubated at 37°C for 30 min. The absorbance was measured at 
562 nm using a microplate reader (BIO-TEK, Winooski, VT) when the plate cooled to RT. 
2.5. Animal studies 
2.5.1. Mice 
Female Balb/c mice at seven weeks of age, purchased from the Jackson Laboratory (Bar Harbor, 
ME), were used in all animal experiments described in this study. Mice were kept in a pathogen-
free Biosafety level-2 animal facility in the Central Laboratory Animal Facility (CLAF) at 
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University of Arkansas (Fayetteville, AR). All procedures were conducted according to 
Institutional Animal Care and Usage Committee (IACUC) approved protocol #13056. Five mice 
were raised in each cage and they were labeled by 0-2 cuts on their left or right ear as: blank (B), 
left-1 (L-1), left-2 (L-2), right-1 (R-1) and right-2 (R-2). 
2.5.2. Vaccine preparation 
The iron oxide nanoparticles (IONs) coating with NTA-Ni (SHT) or with COOH (SHP) were 
prepared by the Ocean Nanotech LLC and kept at 4°C during delivery. For conjugation, SHT 
particle was mixed with HAs protein (~200 µg/ml) on a rotary shaker at 4 °C for 2 h (n ION: n 
Protein=1:5 as suggested by the company); SHP was mixed with HAs protein as negative control. 
A portion of 20 μl of the ION-HAs mixture was loaded to each well of 1% agarose gel to 
confirm that proteins are bound to the particle. For preparation of the nano-vaccines, larger 
amount of HAs were bound to SHT using method as described above. Unbounded HAs proteins 
were removed by centrifugal filter (100 kDa, EMD Millipore), centrifuging at 14,000 rpm for 20 
min at 4 C. Their concentration (in the filtration liquid) was measured by BCA assay (described 
in 2.4.4) so that the loading efficiency of HAs could be calculated. The other kind of nano-
vaccines were prepared by mixing HAs with SHP without specific binding. For all the groups 
(n=3), mice were injected with the same volume (50 µl). Nano-vaccines for injection of mice in 
the same group were prepared in one 1.5 ml tube and buffer 3 in the dialysis step was used to 
adjust the total volume. Because there was space in the needle hub, nano-vaccine with a total 
volume of 300 µl (doses for 6 mice) was prepared for each group.  
2.5.3. Immunization 
In the preliminary experiment, SHT-HAs nano-vaccines carrying 2 μg or 4 μg recombinant HAs 
proteins were investigated. Groups of seven-week-old female Balb/c mice (n=3) were used in 
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order to provide statistically meaningful data. The nano-vaccines were injected into mice via 
intramuscular route (i.m.). Complete Freund’s adjuvant (CFA) is a water-in-oil emulsion 
containing killed cells of Mycobacterium butyricum and used in initial injections, while 
incomplete Freund’s adjuvant (IFA), which lacks this bacterium, is used for subsequent 
injections.  Control mice were immunized with 2 μg HAs emulsified 1:1 (v/v) with CFA/IFA 
(Thermo Scientific, Rockford, IL), saline only or SHT only, respectively. Syringes (1 ml) with 
Luer-Loc tip and 26 G×1/2 in. needles from Becton Dickinson (Franklin Lakes, NJ) were applied 
for injection of the HAs emulsified with CFA/IFA, whereas syringes (1ml) with tuberculin slip 
tip and 30 G×1/2 in. needles were used for the rest groups (shown in Fig. 2.4[A]). The area to be 
injected was first swabbed by 70% ethanol to let the skin expose, the tip of the needle was then 
inserted through the skin and into the caudal thigh muscles (Fig. 2.4[B]).  In all cases, the mice 
were injected three times (two weeks between each injection). The weight of each mice was 
recorded and the activity of mice was observed every another day since the prime immunization.  
With experienced manipulation, nano-vaccines carrying 6 μg or 8 μg recombinant HAs proteins 
were investigated. In this experiment, we tested two kinds of IONs: SHT (binding with HAs via 
the chelation of NTA-Ni) and SHP (mixing with HAs without specific binding). Control mice 
were immunized with 6 μg HAs emulsified with CFA/ IFA, 6μg HAs only, saline only or SHT 
only, respectively. Still, the mice were injected three times (two weeks between each injection) 
and the weight and activity of each mouse was recorded every another day since the prime 
immunization. Details of mice immunization are listed in Table 2.2. 
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2.5.4. Bleeding 
To determine the humoral immune responses in the immunized mice by serological evaluation of 
the production of anti-HA immunoglobulin, approximately 100 µl of blood samples were taken 
on day 10, 24 and 38 post-immunization from submandibular vein. As shown in Fig. 2.4 (C),  
Group Vaccine Dose (μg/50μl ) #Mice 
     1 SHT-HAs* 2 3 
2 SHT-HAs* 4 3 
3 HAs+CFA/IFA 2 3 
4 SHT* 0 3 
5 Saline 0 3 
Group Vaccine Dose (μg/50μl) #Mice 
1 SHT-HAs* 6 3 
2 SHT-HAs* 8 3 
3 SHP+HAs* 6 3 
4 SHP+HAs* 8 3 
5 HAs+CFA/IFA 6 3 
6 HAs 6 3 
7 SHT* 0 3 
8 Saline 0 3 
Table 2.2. Experimental mice grouping (vaccination through i.m. route) 
* It has been demonstrated that up to 4.4 mg/injection of IONs does not cause any abnormalities 
or changes in the blood chemistry of mice tested after each of the three immunizations (58) and 
that the total dose of the ION-HAs vaccines, of which the IONs are only a fraction, will be well 
below this amount. 
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goldenrod animal lancets with 4 mm of point length (MEDpoint, Inc., Mineola, NY) were 
applied to collect the blood sample. Detailed procedures for this blood sampling are described 
elsewhere (http://www.medipoint.com/html/directions_for_use1.html). This bleeding procedure 
causes only momentary pain and distress. The 1.5 ml tubes those contained the collected blood 
samples stood at RT for 3 h and was then centrifuged at 2,500 rpm for 10 min. The supernatant 
(serum containing anti-HA antibody) was transferred to PCR tubes and kept at -20C. 
Fig. 2.4. A. Syringes and needles used in mice immunization. Upper: SHT 
conjugated with HAs; Below: HAs emulsified with CFA (Photo taken by the author 
of the thesis); B. The site of intramuscular injection of mice (adapted from 
http://www.theodora.com/rodent_laboratory/injections.html); C. Bleeding from 
submandibular vein (adapted from www.medipoint.com). 
B. 
 
A.  
 
C. 
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2.5.5. Enzyme-linked Immunosorbent Assays (ELISA) 
Costar Flat Bottom High-binding 96-well EIA/RIA plates (Fisher Scientific) were coated with 
HA proteins (2 μg/ml) of influenza virus A/Vietnam/1203/2004 (H5N1) from BEI resources. The 
HA proteins were dissolved in coating buffer (0.16% Na2CO3, 0.292% NaHCO3, 0.016% NaN3, 
pH 9.6, filtered with 0.2μl filter). A portion of 100 μl of HA proteins per well was added to the 
96 well plates and incubated overnight at 4C. The next day, the coating buffer was removed and 
plates were washed twice by TBST (20 mM Tris-base, 150 nM NaCl, 0.05% Tween-20, pH 7.3). 
A portion of 200 μl blocking buffer (20 mM Tris-base, 150 nM NaCl, pH 7.3, 0.05% Tween-20, 
1% BSA) was then added to each well. After 2 h blocking at RT, plates were washed with TBST 
four times. After that, thawed mouse sera were 2-fold sequentially diluted in the blocking buffer. 
A volume of 100 μl of these 2-fold sequentially diluted sera was added to each well and 
incubated for 2 h at 37C. Plates were then washed with TBST four times. Afterwards a portion 
of 100 μl of 5,000 diluted Goat anti-mouse IgG Biotinylated Affinity (R&D, Fisher Scientific) in 
blocking buffer was added to each well and incubated for 1h at 37C. Plates were then washed 
by TBST four times. A portion of 100 μl of 1,000 diluted Streptavidin-Alkaline Phosphatase 
(R&D, Fisher Scientific) in blocking buffer was added to each well and incubated for 1 h at 37C. 
Plates were then washed by TBST five times. A volume of 100 μl p-Nitrophenyl Phosphate 
Liquid Substrate (MP Biomedicals, Fisher Scientific) was added to each well and incubated in 
dark for 25 min. The reaction was stopped by addition of 50 μl of 2 M NaOH to each well and 
the color intensity was measured immediately at 405 nm and 630 nm with a microplate reader 
(BIO-TEK). Sera collected from mice injected with saline served as negative control. 
Serum samples were 2-fold diluted from 2-3-2-8 dilution. Further dilutions were performed if 
necessary. The endpoint titer was defined as the reciprocal of the serial serum dilution at which 
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the (OD405nm-OD630nm) was above 0.2, which was also larger than the mean plus three standard 
deviations (CN+ 3SD) of the value of the negative control samples. Values of p for differences 
between mean titer of the diversely immunized animal groups were determined by paired 
Student t-test using Excel. A 95% confidence interval will be applied to determine the statistical 
significance of differences between groups.  
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III. RESULTS AND DISCUSSION 
3.1. Construction of pTAHAs plasmid 
To construct the pTAHAs plasmid, we inserted the HAs gene fragment into a pTAGBP vector 
and replaced the GBP gene with HAs. The HAs fragment (HA without cytoplasmic and 
transmembrane domain sequences) was amplified by PCR, as described in 2.1.3. After the 
reaction, a portion of 5 μl PCR product was removed for electrophoresis. A bright band was 
detected, as shown in Fig. 3.1., which indicated the HAs sequence of correct size (1562 bp) was 
amplified.  
                                                                
 
 
 
 
 
 
 
 
 
 
 
 
The PCR products as well as the pTA vector was followed being digested by SalI-HF and SpeI 
double enzyme, both of the products were taken to run the agarose gel electrophoresis.  The sizes 
of the bands were check under UV light. Showing correct sizes, these bands were cut off from 
the gel shortly after they were exposed to UV light. After purification, the digeste vector and 
insertion were ligated by T4 DNA Ligase and followed by heat shock transformation into 
competent E. coli cells. 
10.0- 
8.0- 
6.0- 
5.0- 
4.0- 
3.0- 
2.0- 
1.5- 
1.0- 
0.5- 
Fig. 3.1. PCR products of amplified HAs fragments using designed primers. Lane M, 
1Kb DNA ladder; Lane 1, the PCR product. The samples were analyzed using 0.8% 
agarose gel.  
 
Kb         M          1 
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The second day after the overnight incubation, two colonies were picked up from the LB plate 
with selective antibodies by loop. The plasmids of the selected colonies were extracted and 
screened for positive clones using restriction enzyme digeation assay as mentioned above. As 
shown in Fig. 3.2., two bands indicated the HAs was corrected inserted into the vecter. The 
larger band was between 4,000 bp and 5,000 bp, which was close to the size of the original 
backbone (4308 bp) and the small band was of a size similar to that of HAs (1562 bp). 
                                                              
 
 
 
 
 
 
 
 
 
 
 
 
Afterwards, DNA sequencing confirmed that there was there was no point mutation in the 
positive colony identified through the enzyme digestion assay. The resultant plasmid was 
referred as pTAHAs (Fig.2.2.). 
3.2. Detection of the expression of HAs in E.coli 
The expression of HAs is induced by the addition of IPTG. The latter binds with lac repressor 
and releases them from the lac operator so that the transcription of HAs initiated. As the bacteria 
growth entered an exponential growth phase (OD600nm reached 0.6), we added IPTG into the 
Fig. 3.2. Validation of recombinant DNA isolation through enzyme digestion. Lane 
M, 1 kb DNA marker; Lane 1, plasmid extracted from selected colony pTAHAs#1. The 
plasmid was digested with Spe I-HF and Sal I restriction enzymes and analyzed through 
electrophoresis using 0.8% agarose gel.  
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culture to a final concentration of 1mM in order to induce the expression of HAs. 1 ml culture 
was collected over a 10-h time period, with 1-h interval as mentioned in 2.3.1. The concentration 
of cells were measured as the absorbance at 600nm. The growths of induced and non-induced 
bacterial were compared (Fig. 3.3.). The bacterial without induction kept growing to an OD 
above 4 at 10 h, while the one with induction stopped growing since 4 h and their OD was 
maintained below 1. The obvious difference of growth speed also indicated that the expression of 
HAs protein brought growth pressure to the bacterial cells. 
Next, we determined the solubility of the expressed HAs proteins and the optical induction time 
to gain highest expression level through SDS-PAGE assay. The samples collected as described 
above were treated by B-PER II bacterial protein extraction reagent as mentioned in 2.3.2., and 
the soluble proteins expressed by E.coli cells located in the supernatant after this step. Same 
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Fig. 3.3.The growth curve of E.coli DH5α harboring pTAHAs plasmid. Cells 
were grown in LB medium containing 0.4% glucose and 100µg/ml Ampicillin. 
IPTG was added to a final concentration of 1 mM at 2.5 h when OD600nm approach 
0.6. The E.coli growth was observed over 10 h culture period. 
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amount of extraction reagent was added to the pellet, and the latter as well as the supernatant 
were mixed with loading buffer and heated. In this way, the insoluble proteins were released 
from the inclusion bodies.  
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The strong bands at position of 58.7 kDa in Fig. 3.4 (A) indicated that the HAs was expressed in 
E.coli cells. For there was no apparent bands in Fig. 3.4 (B), the expressed HAs were insoluble 
and located in inclusion bodies. It is noted that in Fig. 3.4 (A) the density of two bands between 
35 kDa and 55 kDa was also increased. The larger band (L) showed in the sample before 
Fig. 3.4. Determination of optimal induction period of HAs expression in 
recombinant DH5α/pTAHAs by SDS-PAGE assay. A) Pellet (insoluble fraction); 
B) supernatant (soluble fraction); Lane: M, Protein ladder; 1, recombinant 
DH5α/pTAHAs before induction; 2-8, 0.5-6.5 h post induction; 9, recombinant 
DH5α/pTAHAs without induction 3.5 h after IPTG was added to the other culture. 
The proteins were separated by 10% SDS-PAGE gel. 
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induction (Lane 1), the non-induced sample (Lane 9), so it is the bacteria’ own protein. On the 
other hand, the smaller band (S) did not show at either Lane 1 or Lane 9. It is possible that 
degradation happened during this process. Because the expressed HAs carried a His-tag at its C-
terminal, the extra bands could be further removed during His-tag specific purification method. 
From Fig. 3.4 (A), it seems that the HAs started to express as early as 0.5 h post induction, and 
the expression level reached the highest between 3.5-4.5 h post induction. Because the 
concentration of samples collected 3.5 h post induction had higher cell concentration (Fig. 3.3.), 
we chose 3.5 h as optical induction time in order to cover the largest yield of bacterial cells in the 
following experiments. 
 
                                                kDa    M       1        2              3         4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5. Comfirmation of HAs expression in recombinant DH5α/pTAHAs. A) 
Western blotting assay; B) SDS-PAGE assay; Lane: M, Protein ladder; 1, 
recombinant DH5α/pTAHAs 3.5 h after induction (pellet, insoluble fraction, 10 fold 
dilution); 2, recombinant DH5α/pTAHAs without induction 3.5 h after IPTG was 
added to another sample; 3, recombinant DH5α/pTAHAs after induction (pellet, 
insoluble fraction); 4, recombinant DH5α/pTAHAs without induction 3.5 h after 
IPTG was added to another sample. The proteins were separated by 10% SDS-
PAGE gel. 
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To further confirm that the HAs was expressed as insoluble protein, we conducted Western Blot 
assay. The mouse anti-HA antibody was applied as primary antibody and anti-mouse IgG HRP 
conjugated antibody was applied as secondary antibody to detect HAs as described in 2.3.3. 
There was only one band in Fig. 3.5 (A), which revealed that the proteins expressed in the 
inclusion bodies were HAs. Also, same as the results we observed in SDS-PAGE assay, there 
was no HAs protein in the soluble fraction of the collected sample. HAs specific antibody only 
recognized certain epitopes of HA protein, therefore the fact that the band S observed in Fig. 
3.4.did not appear in Fig. 3.5 (A) did not exclude its possibility to be degraded parts of HAs. 
3.3. Purification of HAs proteins 
 
 
 
 
 
 
 
 
 
After confirmation of the expression of HAs in E.coli cells, we worked on the purification of this 
recombinant protein. Culture of large volume (400-500ml) was incubated and IPTG was added 
to a final concentration of 0.1mM when the cell density reached OD600=0.6. All the culture 3.5 h 
post induction was collected and the soluble fraction was removed by B-PER II bacterial protein 
Fig. 3.6. Elution pattern of HAs from Ni-NTA column. The recombinant proteins 
with His-tag were eluted from the NTA-Ni column under pH 5.0.  Lane 0. Wash 
fraction; Lane 1-8, elute fraction (1ml/tube). The peak of absorbance appeared 
between fraction 2 and 3 which indicates that large amount of HAs were eluted from 
the column. 
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extraction reagent as mentioned in 2.3.2. The inclusion bodies left in the insoluble fraction were 
broken by 8 M urea (buffer B, pH 8.0) to release the insoluble proteins which contains HAs.  
Tubes (1.5 ml) were prepared to collect each fraction during the purification (1 ml/tube). Before 
applying to the affinity column, the sample was filtered to remove any insoluble part that might 
block the column and affect the yield and purity of the final product. The filtered sample was 
then loaded to a pre-equilibrated column filled with 1ml Ni-NTA resin at a low speed (0.2 
ml/min) to make sure that HAs with His-tag have enough time to bind Ni chelated on the NTA. 
Afterwards, around 10ml buffer B was applied to wash away the unbound proteins. 30-40 ml 
washing buffer (pH 6.3) was applied to the column until the A280 was below 0.01. The elution 
step also needed to be conducted very slowly. Eight fractions with 1ml each were collected after 
applying buffer D (pH 5.0). The appearance of proteins with His-tag was detected by measuring 
absorbance at 280 nm. In Fig. 3.6., the absorbance patter of eluted fraction had a peak with a 
value over 0.5 between fraction 2 and 3. This result indicated that large quantity of HAs were 
eluted in these two fractions.  
To further check the purity of the eluted HAs, a partial of 20 μl of the flow-through (FT), the 
wash fraction (W) and each elute fraction (E1-E6) were applied for SDS-PAGE assay. As shown 
in Fig. 3.7., bright bands with the size of HAs appeared in fraction 2 and 3. The proteins in FT 
were proteins which do not have His-tag so that they could not bind with the Ni-NTA resin.  
With the decrease of pH value of the buffers, the binding capability of proteins without His-tag 
decreases as well. Thus, the washing step removed the proteins weakly bound to the resin 
because of continuous appearance of His in its protein sequences which exposed to the outside. 
As shown in W, most of the unspecific binding proteins were eliminated, even few HAs proteins 
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were washed away from the column. In general, we obtained HAs with high purity after 
purification under denaturing conditions.  
Immediately after the completion of purification, we mixed the elution fraction besides the first 
one which contain few wash fraction. To avoid the occurrence of protein precipitation during 
dialysis, the average A280 of the mixture was adjusted to 0.1 by adding extra buffer D. Buffers 
with different concentration of urea were prepared in advance as described in 2.4.3. The 
denatured HAs proteins were refolded during the process to remove the urea in the buffer. In the 
final step of dialysis, the solution of refolded HAs was replaced by 0.9% NaCl containing 25 
mM Tris-HCl (pH 7.5) for future use in animal immunization. Because the volume of vaccine 
mixture could be injected into mice intramuscularly was limited, we concentrated the dialyzed 
proteins by Amicon size-cut filter tubes. During this process, proteins of size smaller than up to 
30kDa would be removed. As a result, the purity of the HAs was improved again. Finally, we 
could collect ~250µg recombinant HAs from 500ml initial bacterial culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7. SDS-PAGE assay of eluted HAs from Ni-NTA column. Lane: M, protein 
ladder; SL, 5× diluted loading sample; FT, 2× flow through; W, wash fraction; E1-
6, elution fractions. The HAs were eluted mainly at fraction 2 and 3 which accords 
with the absorbance pattern. 
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3.4. Conjugation of HAs with ION 
To confirm that the recombinant HAs were bound to the nanoparticles prepared by Ocean 
Nanotech LLC, the mixture of 4.4 ng SHT (IO-NTA-Ni) and 1.25 μg HAs protein at 4C for 2 h 
(nIO:nProtein=1:5 as suggested by company) was loaded to 1% agarose gel for electrophoresis; 
4.4 ng SHP (IO-COOH) was also mixed with 1.25 μg HAs protein as negative control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Fig. 3.8, Lane 2 showed that SHT conjugated with HAs proteins were evenly distributed on 
the gel above the position of SHT only. The binding of HAs increased the size of the 
nanoparticles and decreased the positive charge of the nanoparticles. It is noted that in lane 4, 
SHP had a few unspecific binding with HA proteins as well. Therefore, HAs were successfully 
bound to IO-NTA-Ni in a solution containing 10 mM Tris-HCl, 0.1 M NaCl, pH 7.5.  
During the preparation of vaccination, we also quantified the HAs loaded onto SHT. The HAs 
loading efficiency of SHP was determined indirectly by comparison of protein concentration 
before and after conjugation reaction detected by BCA assay. The quantification of the loaded 
HAs was calculated using the following equation: 
                    Protein loading efficiency (mg/mg) = (Cp1 × V1-Cp2 ×V2) / (Cp1 ×V1)              
1       2       3       4 
 
 Fig. 3.8. Agarose gel electrophoresis analysis of HAs protein conjugated to 
IO-NTA-Ni nanoparticle (Ocean Nanotech). Lane 1-4, 1% Agarose gel, 
(Lane 1) SHT, (Lane 2) SHT mixed with HAs proteins, (Lane 3) SHP and (Lane 
4) SHP mixed with HAs proteins. 
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Cp1 is the concentration of initial concentrated HAs proteins with an initial volume (V1) added to 
the mixture. Cp2 is the concentration of the free HAs proteins in the filtration liquid of a filtration 
volume (V2).  After filtration, few free HAs left in the filtration liquid, and the loading efficiency 
is ~90% after calculation.   
3.5. Detection of humoral immunity in immunized mice 
3.5.1. The symptoms of experimental mice 
The injections were performed at around 5-6 pm of a day (routes shown in Fig. 3.9 (A)). The 
seven-week-old mice were always very active at this time. A mouse was restrained by single 
hand and the other hand performed the injection. After being restrained, most of the mice had 
accelerated breathing accompany with slight trembling. It was very frequent that they excreted 
during the injection. Few mice kicked or struggled, which may because the tip of the needle 
touched their femur or sciatic nerves, which should be avoided. The activity of the mice was 
relatively decreased and they were easy to be scared after the injection, but no intumescence or 
allergy was observed at the injection site. Ten days after each injection, blood samples were 
collected from submandibular vein.  
During bleeding, the strength used to hold the skin on the back of the mouse’s neck may 
influence the localization of the correct bleeding site. Under very few circumstances, the blood 
came out from the mouse’s ear because the puncture was a little bit high towards the ear. The 
excessive loss of blood caused severe convulsions and distinct decline of activity in one mouse. 
After received a subcutaneous injection of saline solution at the base of a fold of loose skin (area 
at the neck), the mouse behaved normally next day.   
Serum is the blood plasma with the fibrinogens removed and contains neither any blood cells nor 
clotting factor. As for the separation of serum from the coagulated blood sample, sometimes its 
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color was orange red instead of light yellow due to the occurrence of hemolysis (break of red 
cells). From the results of ELISA which will be presented later, the leak of red blood cells did 
not influence the detection of HA-specific antibodies.  
The weight of mice was monitored every another day at around 5-6 pm. Depends on various 
conditions of diet and excretion of each mouse at that moment, its weight was not stable. Still, 
the tendency of weight indicates the basic health status of the mice after immunization. As 
shown in Fig. 3.9 (B), their weights maintained within 98.3%-112.4% of original weights, 
without apparently changes.    
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Fig. 3.9. A. The route of administration of nano-vaccines in mice. Groups of 
Balb/c mice were immunized every two weeks and the blood samples were collected 
ten days post each immunization. B. Mice weight tendency. The body weight of 
every another day was compared with original weight of each individual mouse.  
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3.5.2. Immunogenicity of nano-vaccine tested in mice 
The HA-specific antibodies titers generated in different groups of immunized mice were detected 
using ELISA. The results of preliminary experiments showed that mice immunized with SHT 
binding with 2 µg or 4 µg HAs did not elicit the production of anti-HA IgG until the second 
boost immunization and average log2 titers of the generated IgG were very low (< 4), which 
indicated that the doses of 2 µg or 4 µg were not sufficient to elicit effective humoral immune 
response in immunized mice. Thus, here we analyzed the results of the latter experiments (data 
listed in table 3.1). Two weeks after the second boost immunization, HA-specific antibodies 
were detected in all the immunized groups except for those injected with saline and SHT (Fig. 
3.10). The generation of HA-specific antibodies also indicated that an increasing humoral 
immune response was stimulated in experimental mice after vaccination.  
Table 3.1. Mean log2 titers of HA-specific antibodies generated in mice of each group. 
 
Groups 
HA-specific log2 titer 
 Prime  Boost Second boost 
Saline 0.00±0.00 0.00±0.00 0.00±0.00 
SHT 0.00±0.00 0.67±0.58 1.00±1.00 
HAs-6 0.67±1.15 3.00±1.00 6.00±2.64 
SHT-6 0.00±0.00 2.33±1.53 6.67±3.51 
SHT-8 0.00±0.00 1.67±1.15 5.67±2.08 
SHP-6 0.00±0.00 1.67±1.15 3.67±2.52 
SHP-8 0.00±0.00 1.67±0.58 6.33±1.53 
HAs6-adj 1.67±0.58 8.67±0.58 12.00±0.00 
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Because the number of repeat in each group was relatively small, the individual differences were 
relatively large in the results. As a result, although SHT-6 showed a higher mean titer than HAs6, 
its titer was not significantly higher than that of HAs6 at a 95% confidence interval, which 
indicates that the conjugation of 6 µg HAs to SHT did not enhance the HA-specific antibody 
responses in immunized mice. Similarly, although SHP-6 showed a lower mean titer than SHT-6, 
its titer was not significantly lower than that of SHT-6 at a 95% confidence interval. This result 
suggests that the binding of ION with HAs or not did not influence the production of anti-HA 
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Fig. 3.10. ELISA for HA-specific IgG elicited in immunized mice. Sera from three 
mouse per group were collected ten days post each immunization and analyzed for the 
production of anti-HA IgG via ELISA. Antibody titers are expressed as the log2 values of 
the endpoint titers. Mice were immunized intramuscularly with 50µl mixture containing 6 
µg/8 µg recombinant HAs conjugated with SHT (SHT-6/SHT-8), those mixed with SHP 
(SHP-6/SHP-8) or those emulsified with CFA/IFA (HAs6-adj). Mice were also immunized 
intramuscularly with 50µl solution containing 6µg recombinant HAs only (HAs-6), SHT or 
saline. Error bars, SD, n=3. 
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antibodies in immunized mice. The increase of doses did not significantly improve the antibody 
titer in SHT-6 and SHT-8, but in SHP-6 and SHP-8. On the other hand, 6 µg HAs emulsified 
with CFA/IFA stimulated significant higher titer of anti-HA antibodies in immunized mice after 
the second boost immunization. The statistical significant difference analysis was presented in 
Table 3.2. 
Table 3.2. Significant comparison between HA-specific IgG elicited in different groups of 
immunized mice after second boost immunization. P value of paired student t-test: a=0.211, 
b=0.059, c=0.030, d=0.333, e=0.094, f=0.029.* Significantly higher (P< 0.05) than antibody titer 
of HAs-6. ** Significantly higher (P< 0.05) than antibody titer of SHP-8. 
 
We expected that the average log2 titers of anti-HA IgG could reach 12~15 in mice immunized 
with nano-vaccines or HAs emulsified with CFA/IFA after second boost immunization as shown 
in Pusic K’s work (58), but the nano-vaccines did not improve the HA-specific antibody 
production to this level in immunized mice. Many factors may cause the experimental results not 
consistent with our assumptions. First, the amount of HAs in nano-vaccines may be 
overestimated. The BCA assay reflected the total amount of purified proteins, which included 
few impurity. Besides, degradation of HAs may happen during different steps of vaccine 
Groups 
HA-specific log2 titer 
 Mouse 1  Mouse 2 Mouse 3 Mean ± SDp 
HAs-6 7 3 8 6.00±2.64a,b,c 
SHT-6 7 3 10 6.67±3.51a,d,e 
SHT-8 8 4 5 5.67±2.08d 
SHP-6 6 1 4 3.67±2.52b,e,f 
SHP-8 8 5 6 6.33±1.53f** 
HAs6-adj 12 12 12 12.00±0.00c* 
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preparation, such as the conjugation with IONs, and the removal of unbounded HAs by 
centrifugal filter. Degradation can also occur during the delivery of vaccines before immunizing 
the mice.  Each possibility may lead to a reducing amount of active antigens in the nano-vaccines, 
so there is not sufficient dose of HAs together with IONs to produce comparable level of HA-
specific antibodies as those emulsified with CFA/IFA. To solve these problems, we can handle 
higher dose of HAs; we can also modify the condition of purification and dialysis to protect the 
proteins from degradation. Second, the IONs may not be efficiently captured by APCs to make 
HAs “visualized” by the immune system of mice. Particle size is very important for antigen 
uptake by APCs and routes of the CD4+ T cell response (59; 60). The particles investigated in 
this study are of a size of 10 nm, entering APCs by receptor-mediated endocytosis together with 
HAs. The enzymes in endosome will detach the conjugation between IONs and HAs, and 
process the proteins into peptides. We can replace the IONs with those of larger diameters or 
additional surface modification to enhance their targeting to APCs. Third, imperfect operation in 
animal immunization may affect the accuracy of the results. Antibody plays significant function 
in adaptive immunity as blocking virus binding and entry into host cells, therefore, we evaluate 
the immunogenicity of each vaccine by measuring the level of generated HA-specific antibody in 
immunized mice. However, intramuscular injection demands experienced handling, and slight 
variation of the injected volume is easy to take place. Also, the vaccine preparation may not be 
mixed thoroughly before injection, so the HAs together with IONs are not distributed evenly in 
the mixture. All of these factors may lead to poor repeatability of the HA-specific antibody titers 
of mice in the same group, which impacts the significant analysis of these data. To compensate 
errors resulted from these reasons, we should increase the number of animals in each group. 
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IV. CONCLUSIONS AND FUTURE WORKS 
The HA glycoprotein is considered as a key target for both cellular and humoral immune 
response against influenza virus. In this study we reported the sub-cloning and expression of 
HAs from a H5N1 influenza virus in E.coli. Our experimental results suggested that the 
glycosylation is not necessary for recombinant HAs to elicit humoral immune response in 
immunized mice, and the E.coli expression system is able to produce subunit HAs vaccine 
against influenza virus. We also showed that the HAs is expressed as early as at 0.5 h post 
induction, and reaches highest expression level between 3.5-4.5 h after the addition of inducer 
IPTG. The expression of HAs brings growth pressures to the bacterial cells. Using the 
purification and refolding methods developed in this study, we collected recombinant HAs 
protein from the bacterial culture at a yield of 250 µg/500 ml. Later, we demonstrated that the 
concentrated HAs proteins are able to bind with SHT (ION-NTA-Ni) nanoparticles at a high 
loading ratio ~90%. In the animal studies, we found that 6 µg recombinant HAs was sufficient to 
stimulate increasing production of HA-specific IgG in mice post three-time immunization. 
Meanwhile, we noticed that HAs conjugated with SHT did not perform significant improvement 
of HA-specific antibody production in immunized mice, compared with HAs. 
Future works need to be focused on the modification of nano-vaccines in order to continue the 
investigation of IONs as potential delivery platform of influenza vaccine. On one hand, we could 
improve the activity of recombinant HAs by optimizing conditions of dialysis, conjugation with 
IONs and vaccine preservation to reduce the protein degradation. We could also modify the 
IONs by increasing their diameter or attaching molecules that facilitate APC targeting to their 
surface. On the other hand, we could keep exploring the immunogenicity of current vaccine 
preparation carrying higher dose of HAs. ELISA in this study only detected the generation level 
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of total IgG, which peaks 4-6 weeks after natural infection. Subtypes of IgG could be further 
detected in order to determine what type of them dominates in the humoral immune responses of 
immunized mice. Long-term immune protection provided by the nano-vaccine can be detected 
on the sera collected half a month or longer post the second boost injection. Although we 
anticipated that conjugation of HAs with IONs could enhance the humoral immune responses in 
mice, IONs may augment the cellular immune responses instead. Enzyme-linked immunosorbent 
spot assay (ELISPOT) will be performed to measure the increase number of IFN-γ-secreting T 
cells from freshly collected splenocytes of immunized mice. The same assay could be applied to 
detect HA-specific interleukin-12 (IL-12) or interleukin-4 (IL-4) production in immunized mice, 
which indicate whether the IONs activate the CD4+ T cells via Th1 or Th2 route. The HA-
specific antiviral CD8+/cytotoxic T cell (CTL) responses can be characterized by chromium 
[51Cr]-release assay.  
After modification of the nano-vaccines from different aspects as mentioned above, we expect 
that mean log2 titers of anti-HA IgG could be higher than 13 in mice immunized with nano-
vaccines. Because high total IgG level does not guarantee that sufficient protective antibodies 
against virus strain are elicited in immunized mice, we will perform the hemagglutination 
inhibition (HI) assay to determine functional anti-HA antibody titer. Also, we could perform in 
vitro microneutralization (MN) assay, a highly sensitive and specific assay, to measure the serum 
neutralizing capacity against the homologous H5N1 influenza virus in immunized mice before 
moving forward to the assessment of their functional protective efficacy by host challenge 
against H5N1 strain.  
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